These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 31356114)

  • 1. The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential.
    Anthony C; Mladkova-Suchy N; Adamson DC
    Expert Opin Investig Drugs; 2019 Sep; 28(9):787-797. PubMed ID: 31356114
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
    Chinot OL
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
    Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
    World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
    Winkler F; Osswald M; Wick W
    Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic Therapy of High-Grade Gliomas.
    Jo J; Wen PY
    Prog Neurol Surg; 2018; 31():180-199. PubMed ID: 29393186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis inhibitors in tackling recurrent glioblastoma.
    Hundsberger T; Reardon DA; Wen PY
    Expert Rev Anticancer Ther; 2017 Jun; 17(6):507-515. PubMed ID: 28438066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
    Hall WA; Vallera DA
    Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic targeting of VEGF in the treatment of glioblastoma.
    Robles Irizarry L; Hambardzumyan D; Nakano I; Gladson CL; Ahluwalia MS
    Expert Opin Ther Targets; 2012 Oct; 16(10):973-84. PubMed ID: 22876981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.
    Angara K; Borin TF; Rashid MH; Lebedyeva I; Ara R; Lin PC; Iskander A; Bollag RJ; Achyut BR; Arbab AS
    Neoplasia; 2018 Oct; 20(10):1070-1082. PubMed ID: 30236892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of antiangiogenic therapies for glioblastomas.
    Arrillaga-Romany I; Reardon DA; Wen PY
    Expert Opin Investig Drugs; 2014 Feb; 23(2):199-210. PubMed ID: 24320142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
    Miletic H; Niclou SP; Johansson M; Bjerkvig R
    Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
    Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
    Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
    [No Abstract]   [Full Text] [Related]  

  • 14. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
    Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
    Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.
    Ahir BK; Engelhard HH; Lakka SS
    Mol Neurobiol; 2020 May; 57(5):2461-2478. PubMed ID: 32152825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic therapies in glioblastoma multiforme.
    McNamara MG; Mason WP
    Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations.
    Nery de Albuquerque Rego G; da Hora Alves A; Penteado Nucci M; Bustamante Mamani J; Anselmo de Oliveira F; Gamarra LF
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis in human brain tumors: screening of drug response through a patient-specific cell platform for personalized therapy.
    Guarnaccia L; Navone SE; Trombetta E; Cordiglieri C; Cherubini A; Crisà FM; Rampini P; Miozzo M; Fontana L; Caroli M; Locatelli M; Riboni L; Campanella R; Marfia G
    Sci Rep; 2018 Jun; 8(1):8748. PubMed ID: 29884885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.
    Onishi M; Kurozumi K; Ichikawa T; Date I
    Neurol Med Chir (Tokyo); 2013; 53(11):755-63. PubMed ID: 24162241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenic inhibition in high-grade gliomas: past, present and future.
    Jo J; Schiff D; Purow B
    Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.